Enveric Biosciences (ENVB) announced significant progress in the chemistry, manufacturing, and controls development of its lead candidate, EB-003. The company stated it has completed key activities, including identifying a pharmaceutically compatible salt form, developing a scalable synthetic route, and successfully producing a 1-kilogram batch to support upcoming Investigational New Drug application activities. “These advancements, combined with our preclinical data, continue to build momentum for EB-003 as we move closer to first-in-human studies,” said Joseph Tucker, CEO of Enveric Biosciences.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENVB:
- Enveric Biosciences files to sell 5.02M shares of common stock for holders
- Enveric Biosciences Closes Warrant Exercise Deal
- Enveric Biosciences publishes two peer-reviewed research papers
- Enveric Biosciences receives FDA response, streamlines path for EB-003
- Enveric Biosciences Relocates Headquarters to Cambridge